---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-006097"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2022-09-14T23:59:59+00:00"
generated_at: "2026-06-23T09:52:15.621544+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# BioCryst names Dr. Bill Sheridan CDO and Dr. Ryan Arnold CMO effective Sept 15, 2022

## Summary
- Dr. William Sheridan transitions from CMO to Chief Development Officer, focusing on pipeline advancement.
- Dr. Ryan Arnold promoted from SVP Global Medical Affairs (since March 2022) to Chief Medical Officer.
- Both join Dr. Helen Thackray (Chief R&D Officer) as physicians on leadership team.
- Dr. Sheridan joined BioCryst in 2008; Dr. Arnold has 20+ years industry experience including at Amgen, Genzyme, Biogen.

## SEC filing metadata
- accession: 0001171843-22-006097
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2022-09-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184322006097/0001171843-22-006097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184322006097/f8k_091422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-006097
- JSON: https://secwatch.observer/filing/0001171843-22-006097.json
- Plain text: https://secwatch.observer/filing/0001171843-22-006097.txt

## Key facts
- Executive change
  Ryan Arnold was appointed as Chief Medical Officer at BIOCRYST PHARMACEUTICALS INC.
  - Action: will serve
  - Role: Chief Medical Officer
  source text: Also effective September 15, 2022, Dr. Ryan Arnold will serve as the Company’s new Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184322006097/0001171843-22-006097-index.htm
- Executive change
  William P. Sheridan changed role as Chief Development Officer at BIOCRYST PHARMACEUTICALS INC.
  - Action: will serve
  - Role: Chief Development Officer
  source text: Effective September 15, 2022, William P. Sheridan, MBBS, will serve as Chief Development Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184322006097/0001171843-22-006097-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.